CHRNA7 and schizophrenia: Currently available treatments for schizophrenia alleviate positive, but not cognitive or negative symptoms, so the evidence suggests that drug development targeting the α7nAChR remains a viable option for improving cognitive or negative symptoms in schizophrenic patients receiving antipsychotic drugs.